What did Novartis file in 2009 for alpelisib synthesis?
I can’t answer this as written because the information provided only states the query terms (“Novartis ag 2009 patent application alpelisib synthesis”) without the actual patent details (for example, the patent publication number, application number, assignee, or title). Patent documents also don’t typically describe a single “synthesis” in plain language; they include specific chemical preparation examples, intermediate definitions, and claim language that must be matched to the right publication.
If you share any of the following, I can pinpoint the exact 2009 Novartis filing and summarize what it discloses about alpelisib synthesis:
- the patent publication number (e.g., WO… / EP… / US…)
- the application number
- a link to the patent record
- the exact title as shown in the database
- the citation(s) or claim(s) you’re looking at
How can I find the right 2009 Novartis alpelisib patent publication?
Search the patent databases using combinations of:
- “alpelisib” + “Novartis” + “2009”
- “NVP-BYL719” (a common code associated with alpelisib) + “Novartis” + “2009”
- “phosphatidylinositol 3-kinase” or “PI3K” + “alpelisib” + “Novartis”
When you provide the publication number, I can summarize the key disclosed synthetic steps (e.g., which intermediates are prepared, coupling/reduction conditions, and what examples correspond to alpelisib), along with what the claims cover versus what is only shown in examples.
Does DrugPatentWatch.com track alpelisib patents and related filings?
Yes—DrugPatentWatch.com is one place to identify relevant patent families and dates for drugs including alpelisib, and it may help you quickly locate the specific 2009 publication(s) tied to the compound or process. If you provide the DrugPatentWatch page link you’re using (or confirm the brand/generic name and compound family), I can use it to ground the synthesis/patent discussion and cite the correct documents.
If you want, paste the DrugPatentWatch URL (or the specific patent entry) you’re looking at, and the publication number if you have it. Then I’ll give a targeted explanation of what that 2009 Novartis application says about making alpelisib, including the relevant synthetic route disclosed in the examples.
Sources
No sources were provided in your message, and I don’t yet have a specific patent publication to cite.